Real-world effectiveness of single agent enfortumab vedotin (EV) in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC) based on line of therapy and impact of prior platinum (plat) chemotherapy (chemo) and PD-1/PD-L1 inhibitors (PD-1/PD-L1i)

被引：0
|
作者：
Sayegh, N. [1 ]
Jo, Y. Jung [1 ]
Gebrael, G. [1 ]
Tripathi, N. [1 ]
Chigarira, B. [1 ]
Srivastava, A. [1 ]
Nordblad, B. [1 ]
Dal, E. [1 ]
Chehade, C. Hage [1 ]
Maughan, B. L. [1 ]
Gupta, S. [1 ]
Agarwal, N. [1 ]
Swami, U. [1 ]
机构：
[1] Univ Utah Hlth, Huntsman Canc Inst, Salt Lake City, UT USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1029
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2380P
引用
收藏
页码：S1212 / S1212
页数：1
相关论文
共 50 条
  • [21] Radiomics-based prediction model for outcomes of PD-1/PD-L1 immunotherapy in metastatic urothelial carcinoma
    Park, Kye Jin
    Lee, Jae-Lyun
    Yoon, Shin-Kyo
    Heo, Changhoe
    Park, Bum Woo
    Kim, Jeong Kon
    EUROPEAN RADIOLOGY, 2020, 30 (10) : 5392 - 5403
  • [22] Radiomics-based prediction model for outcomes of PD-1/PD-L1 immunotherapy in metastatic urothelial carcinoma
    Kye Jin Park
    Jae-Lyun Lee
    Shin-Kyo Yoon
    Changhoe Heo
    Bum Woo Park
    Jeong Kon Kim
    European Radiology, 2020, 30 : 5392 - 5403
  • [23] The future of immunotherapy in advanced renal cell carcinoma: beyond PD-1/PD-L1 inhibitors
    Nuvola, Giacomo
    Mollica, Veronica
    Massari, Francesco
    Suarez, Cristina
    IMMUNOTHERAPY, 2023, 15 (17)
  • [24] PD-1/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy as second or later-line treatment for patients with advanced non-small cell lung cancer: A real-world retrospective cohort study
    Chen, Shubin
    Wei, Haowen
    Zhao, Wenhua
    Jiang, Wei
    Ning, Ruiling
    Zhou, Shaozhang
    Tan, Liping
    Wang, Huilin
    Su, Cuiyun
    He, Jianbo
    Zeng, Aiping
    Zhao, Yun
    Yu, Qitao
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [25] Improving the Cost Efficiency of PD-1/PD-L1 Inhibitors for Advanced Urothelial Carcinoma: A Major Role for Precision Medicine?
    Sonpavde, Guru
    Dranitsaris, George
    Necchi, Andrea
    EUROPEAN UROLOGY, 2018, 74 (01) : 63 - 65
  • [26] Response to salvage chemotherapy following exposure to PD-1/PD-L1 inhibitors in patients with NSCLC
    Rothschild, S. I.
    Leger, P.
    Castellanos, E. L.
    Pillai, R. N.
    York, S. J.
    Horn, L.
    ANNALS OF ONCOLOGY, 2017, 28
  • [27] Effect of region on the Outcome of Patients Receiving PD-1/PD-L1 Inhibitors for Advanced Cancer
    Wang, Ziheng
    Zhang, Bo
    Zhang, Chenlin
    Ren, Shiqi
    Wang, Wei
    Wang, Yingjing
    Jiang, Tao
    Wei, Hualin
    Li, Yang
    Wu, Qiong
    Chen, Jianfeng
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2019, 74
  • [28] Safety and tolerability of PD-1/PD-L1 inhibitors in elderly and frail patients with advanced malignancies
    Sakakida, Tomoki
    Ishikawa, Takeshi
    Uchino, Junji
    Tabuchi, Yusuke
    Komori, Satoshi
    Asai, Jun
    Arai, Akihito
    Tsunezuka, Hiroaki
    Kosuga, Toshiyuki
    Konishi, Hirotaka
    Hongo, Fumiya
    Inoue, Masayoshi
    Hirano, Shigeru
    Ukimura, Osamu
    Taguchi, Tetsuya
    Takayama, Koichi
    Itoh, Yoshito
    ONCOLOGY LETTERS, 2020, 20 (04)
  • [29] The impact of single agent PD-1 or PD-L1 inhibition on advanced endometrial cancers: meta-analysis
    Kok, P. -S.
    Antill, Y. C.
    Scott, C. L.
    Lee, C. K.
    ESMO OPEN, 2022, 7 (06)
  • [30] Outcomes With First-line PD-1/PD-L1 Inhibition in Advanced Urothelial Cancer: A Single Institution Experience
    Hsu, Miles M.
    Xia, Yuhe
    Troxel, Andrea
    Delbeau, Daniela
    Francese, Kaitlyn
    Leis, Dayna
    Shepherd, Deneuve
    Balar, Arjun, V
    CLINICAL GENITOURINARY CANCER, 2020, 18 (03) : E209 - E216
12345